Express News | Zevra Therapeutics Enters Agreement to Sell Its Rare Pediatric Disease Priority Review Voucher for $150 Million

ReutersFeb 27 07:30 ET

JMP Securities Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $17

Moomoo NewsFeb 27 09:31 ET · Ratings

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA) and Venus Concept (VERO)

TipRanksFeb 27 09:30 ET · Ratings

Zevra Therapeutics Stock Rises on $150M Asset Sale

InvestingFeb 27 07:42 ET

Zevra Therapeutics: Closing to Take Place Within 30-45 Days >ZVRA

Dow JonesFeb 27 07:32 ET

Press Release: Zevra Therapeutics Enters Agreement to Sell Its Rare Pediatric Disease Priority Review Voucher for $150 Million

Dow JonesFeb 27 07:30 ET